Gestational Trophoblastic Disease ECHO-Case Presentation

Video Transcription

Video Summary

The transcript presents a case of a 35-year-old woman in far north Queensland who miscarried at seven weeks in April 2020 and was found to have a partial molar pregnancy (triploidy; initial β-hCG 28,500). Her β-hCG initially declined to very low levels but then plateaued and rose, meeting criteria for persistent gestational trophoblastic disease (GTD). Given low-level disease and ultrasound showing nonspecific fundal thickening, the team opted for a second curettage (hysteroscopy-guided), which showed no residual trophoblastic tissue. β-hCG again slowly rose (peak ~120).<br /><br />Staging/score suggested low-risk disease, with an equivocal small lung lesion (score 1). First-line single-agent chemotherapy was discussed; their center prefers pulse actinomycin-D due to geography and logistics, with evidence of slightly higher primary remission than methotrexate though overall cure approaches 100% with salvage. The patient received four cycles of actinomycin-D but developed resistance, then two cycles of 8-day methotrexate, with continued low-level rise. Repeat imaging was performed before escalation. She ultimately required multi-agent EMACO (11 cycles: 8 to remission plus 3 consolidation), achieving β-hCG <5. Key lessons: “low risk” doesn’t mean “no risk,” partial moles can still need multi-line therapy, second curettage has limited yield/risks, and resistance management may be guided by β-hCG thresholds and restaging.

Asset Subtitle

March 2026, Andrea Garrett & Trevor Tejada-Berges

Keywords

partial molar pregnancy

triploidy

persistent gestational trophoblastic disease

beta-hCG plateau and rise

second curettage hysteroscopy-guided

low-risk GTD staging score

actinomycin-D chemotherapy resistance

methotrexate salvage therapy

EMACO multi-agent chemotherapy